---
company: MANNKIND CORP
ticker: MNKD
form: 8-K
filed: 2026-08-05
accession: 0001193125-26-335016
source: https://www.sec.gov/Archives/edgar/data/899460/000119312526335016/
---

# Mannkind (MNKD) earnings release, August 5, 2026

Mannkind Corp (MNKD) · Form 8-K, Item 2.02 · Filed 2026-08-05 · [SEC filing](https://www.sec.gov/Archives/edgar/data/899460/000119312526335016/)

MannKind Reports Second Quarter 2026 Financial

Results and Provides Business Update

• Achieved three major catalysts to drive future growth: o

Launched the pediatric indication of Afrezza® following FDA approval o

FUROSCIX ReadyFlow™ autoinjector approved for treatment of edema in HF and CKD o

Positive nintedanib DPI Phase 1b data in IPF patients validates continued Phase 2 advancement

• Encouraging early momentum in Afrezza pediatric launch o

1 in 3 of the top 100 pediatric insulin writers have prescribed

• Q2 2026 total revenues of $109.4M, +43% vs. Q2 2025

• Conference call and webcast today at 4:30 p.m. ET

DANBURY,

Conn. and

WESTLAKE

VILLAGE,

Calif.,

August 5,

2026

(GLOBE

NEWSWIRE)

--

MannKind

Corporation

(Nasdaq:

MNKD) a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung diseases, today reported financial results for the second quarter of 2026, and provided a business update.

“This was a transformative period for MannKind, during which we delivered all three major catalysts we set out to achieve in 2026,” said Michael Castagna, Chief Executive Officer of MannKind. “The two recent FDA approvals are expected to fuel our near-term growth opportunities to help patients living with diabetes, heart failure and CKD. The positive Phase 1b INFLO-1 results for MNKD-201 reduces development risk and strengthens our confidence in the ability of our platform to help people living with IPF and other fibrotic diseases. Together, these milestones validate our diversification strategy and position MannKind for sustainable growth.”

Business Update and Upcoming Milestones

Commercial Products

• Revenue from marketed products (Afrezza, Furoscix®) grew 27% from Q1 2026 to Q2 2026

Furoscix

• Furoscix (furosemide injection) generated $22.2 million in net sales for Q2 2026

• Continued growth in Integrated Delivery Networks, increasing doses purchased by 36% over Q1 2026

• Record number of nephrology units dispensed, increasing by 67% over Q1 2026

• Received FDA approval of Furoscix ReadyFlow™ on July 23, 2026, the first and only autoinjector delivering IV-equivalent diuretic therapy for the treatment of edema in adults with heart failure (HF) or chronic kidney disease (CKD); expected to be commercially available in late August

Afrezza

• Afrezza (insulin human) Inhalation Powder generated $17.0 million in net sales for Q2 2026

• Received FDA approval of Afrezza on May 29, 2026 for use in children and adolescents ages 6 and older living with diabetes

• Awarded Breakthrough T1D grant supporting advancement of INHALE-1

ST, a pediatric trial of Afrezza in youth with newly diagnosed type 1 diabetes

Development

Nintedanib DPI (MNKD-201)

• Topline data readout of U.S. Phase 1b INFLO-1 demonstrates safety and tolerability in IPF patients

• Site activation and enrollment underway in the global Phase 2 INFLO-2 study

Ralinepag DPI (MNKD-1501)

• On track for IND filing by year end

• Received a $5 million payment from United Therapeutics (UT) to support the rapid advancement of ralinepag DPI

Corporate Update

• Cash, cash equivalents and investments as of

June 30,

2026, totaled

$111 million

• Closed $50 million private placement on July 24, 2026; proceeds will fund the $45 million CVR payment triggered by the FDA approval of Furoscix ReadyFlow

Second

Quarter

2026

Financial

Results

Revenues

Total revenues for the second quarter of 2026 increased compared to the same period in the prior year due to the addition of Furoscix to our product portfolio through the October 7, 2025 acquisition of scPharma, as well as increases in collaborations and services revenue, and royalties. The increase in collaborations and services revenue was primarily attributable to increased product sold to UT and revenue earned related to the development of ralinepag DPI. The increase in royalties was due to UT’s increase in net revenue from sales of Tyvaso DPI.

Operating Expenses and Other Financial Highlights



Cost of goods sold – commercial, excluding amortization of acquired intangible assets, was $14.4 million for the three months ended June 30, 2026, compared to $4.6 million for the same period in 2025.



The increase is primarily attributable to the inclusion of Furoscix into our product portfolio following the acquisition of scPharma in October 2025. Gross margin percentage decreased in the current period due to the inclusion of Furoscix, which has a lower gross margin percentage than Afrezza.



Research and development expenses were $18.0 million for the three months ended June 30, 2026, compared to $13.7 million for the same period in 2025, an increase of 32%.



The increase was primarily attributable to the development of the Furoscix ReadyFlow Formulation as well as higher personnel costs following the acquisition of scPharma and increased development costs for MNKD-201, which has begun enrolling subjects. The increase was partially offset by lower clinical development expenses resulting from the discontinuation of the ICoN-1 clinical study for MNKD-101 and the completion of the Afrezza pediatric study (INHALE-1).



Selling, general and administrative expenses were $58.3 million for the three months ended June 30, 2026, compared to $31.6 million for the same period in 2025, an increase of 84%.



The increase was primarily related to costs associated with the promotion and support of Furoscix, as well as expanding our field-based teams and activities to support the launches associated with the recent approvals of the pediatric indication for Afrezza and the Furoscix ReadyFlow Autoinjector.

Six Months Ended June 30, 2026

Revenues... (truncated)tfolio through the October 7, 2025 acquisition of scPharma, as well as increases in collaborations and services revenue, and royalties. The increase in collaborations and services revenue was primarily attributable to an increase in revenue earned related to the development of ralinepag DPI. The increase in royalties was due to UT’s increase in net revenue from sales of Tyvaso DPI.

Operating Expenses and Other Financial Highlights



Cost of goods sold – commercial, excluding amortization of acquired intangible assets, was $21.9 million for the six months ended

June 30, 2026, compared to $8.4 million for the same period in 2025.



The increase is primarily attributable to the inclusion of Furoscix into our product portfolio following the acquisition of scPharma in October 2025. Gross margin percentage decreased in the current period due to the inclusion of Furoscix, which has a lower gross margin percentage than Afrezza.



Research and development expenses were $35.2 million for the six months ended June 30, 2026, compared to $24.7 million for the same period in 2025, an increase of 43%.



The increase was primarily attributable to the development of the Furoscix ReadyFlow Formulation as well as higher personnel costs following the acquisition of scPharma and increased development costs for MNKD-201, which has begun enrolling subjects. The increase was partially offset by lower clinical development expenses resulting from the discontinuation of the ICoN-1 clinical study for MNKD-101 and the completion of the Afrezza pediatric study (INHALE-1).



Selling, general and administrative expenses were $112.4 million for the six months ended June 30, 2026, compared to $56.6 million for the same period in 2025, an increase of 98%.



The increase was primarily related to costs associated with the promotion and support of Furoscix, as well as expanding our field-based teams and activities to support the launches associated with the recent approvals of the pediatric indication for Afrezza and the Furoscix ReadyFlow Autoinjector.

Conference

Call and Webcast

MannKind will host a conference call and webcast to discuss these results today at 4:30 p.m. Eastern Time. The webcast will be accessible via a link on MannKind’s website at https://investors.mannkindcorp.com/events-and-presentations. A replay will also be available in the same location within 24 hours after the call and accessible for approximately 90 days.

About

MannKind

MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.

With deep expertise in drug-device combinations, MannKind aims to deliver therapies designed to fit seamlessly into daily life.

Learn more at mannkindcorp.com.

Forward-Looking

Statements

Statements in this press release that are not statements of historical fact are forward-looking statements that involve risks and uncertainties. These statements include, without limitation, statements regarding the timing for expected commercial availability of Furoscix ReadyFlow and the broadened growth potential for Furoscix; the timing of a planned IND filing of ralinepag DPI; expectations regarding MannKind’s ongoing and planned clinical trials and nonclinical studies; and our being positioned for sustainable growth. Words such as “believes,” “anticipates,” “plans,” “expects,” “intend,” “will,” “goal,” “potential,” “prepare,” “opportunity” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon MannKind’s current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with developing product candidates; risks and uncertainties related to unforeseen delays that may impact the timing of clinical trials and reporting data; risks associated with safety and other complications of our products and product candidates; risks associated with the regulatory review process; risks associated with competition; manufacturing risks; market adoption risks; and other risks detailed in MannKind’s filings with the Securities and Exchange Commission (“SEC”), including under the “Risk Factors” heading of its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, being filed with the SEC later today. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.

Tyvaso

DPI is a trademark of

United

Therapeutics

Corporation.

AFREZZA,

FUROSCIX, FUROSCIX READYFLOW,

MANNKIND, and V-GO are trademarks of

MannKind

Corporation.

MannKind Contacts:

Investor Relations

Kate Miranda

Email: ir@mnkd.com

Media Relations

Christie Iacangelo

Email: media@mnkd.com

MANNKIND

CORPORATION

AND

## Financial statements

### Income Statement (Three Months Ended June 30, — Revenues (in thousands))

| | Three Months Ended June 30, – 2026 | Three Months Ended June 30, – 2025 | Three Months Ended June 30, – $ Change | Three Months Ended June 30, – % Change |
|---|---:|---:|---:|---:|
| Afrezza | 17,021 | 18,329 | -1,308 | -7.0% |
| Furoscix | 22,191 |  | 22,191 |  |
| V-Go® | 2,770 | 4,125 | -1,355 | -33.0% |
| Collaborations and services | 35,022 | 22,845 | 12,177 | 53.0% |
| Royalties | 32,370 | 31,228 | 1,142 | 4.0% |
| Total revenues | 109,374 | 76,527 | 32,847 | 43.0% |

### Income Statement (Six Months Ended June 30, — Revenues (in thousands))

| | Six Months Ended June 30, – 2026 | Six Months Ended June 30, – 2025 | Six Months Ended June 30, – $ Change | Six Months Ended June 30, – % Change |
|---|---:|---:|---:|---:|
| Afrezza | 32,294 | 33,216 | -922 | -3.0% |
| Furoscix | 37,684 |  | 37,684 |  |
| V-Go | 5,911 | 8,211 | -2,300 | -28.0% |
| Collaborations and services | 58,536 | 52,221 | 6,315 | 12.0% |
| Royalties | 65,119 | 61,233 | 3,886 | 6.0% |
| Total revenues | 199,544 | 154,881 | 44,663 | 29.0% |

### Income Statement (Three Months Ended June 30, — CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands except per share data))

| | Three Months Ended June 30, – 2026 | Three Months Ended June 30, – 2025 | Six Months Ended June 30, – 2026 | Six Months Ended June 30, – 2025 |
|---|---:|---:|---:|---:|
| Revenues: | Commercial product sales | 41,982 | 22,454 | 75,889 | 41,427 |
| Revenues: | Collaborations and services | 35,022 | 22,845 | 58,536 | 52,221 |
| Revenues: | Royalties | 32,370 | 31,228 | 65,119 | 61,233 |
| Revenues: | Total revenues | 109,374 | 76,527 | 199,544 | 154,881 |
| Expenses: | Cost of goods sold – commercial, excluding amortization of acquired intangible assets | 14,409 | 4,607 | 21,917 | 8,375 |
| Expenses: | Cost of revenue – collaborations and services | 15,131 | 15,961 | 25,094 | 29,709 |
| Expenses: | Research and development | 18,001 | 13,675 | 35,232 | 24,697 |
| Expenses: | Selling, general and administrative | 58,302 | 31,622 | 112,389 | 56,636 |
| Expenses: | Amortization of acquired intangible assets | 4,367 |  | 8,734 |  |
| Expenses: | (Gain) loss on foreign currency transaction | -486 | 5,363 | -1,804 | 7,872 |
| Expenses: | Total expenses | 109,724 | 71,228 | 201,562 | 127,289 |
| Expenses: | (Loss) income from operations | -350 | 5,299 | -2,018 | 27,592 |
| Other income (expense): | Interest income, net | 1,022 | 1,832 | 2,452 | 3,788 |
| Other income (expense): | Interest expense | -11,894 | -285 | -19,372 | -4,930 |
| Other income (expense): | Interest expense on liability for sale of future royalties | -510 | -3,473 | -3,073 | -7,050 |
| Other income (expense): | Interest expense on financing liability | -2,414 | -2,433 | -4,807 | -4,843 |
| Other income (expense): | Loss on settlement of debt |  |  | -917 |  |
| Other income (expense): | Other expense | -4,992 |  | -7,769 |  |
| Other income (expense): | Total other expense | -18,788 | -4,359 | -33,486 | -13,035 |
| Other income (expense): | (Loss) income before income tax (benefit) expense | -19,138 | 940 | -35,504 | 14,557 |
| Other income (expense): | Income tax (benefit) expense | -106 | 272 | 147 | 731 |
| Other income (expense): | Net (loss) income | -19,032 | 668 | -35,651 | 13,826 |
| Other income (expense): | Net (loss) income per share – basic | -0.06 | 0 | -0.12 | 0.05 |
| Other income (expense): | Weighted average shares used to compute net (loss) income per share – basic | 309,191 | 304,954 | 308,732 | 304,222 |
| Other income (expense): | Net (loss) income per share – diluted | -0.06 | 0 | -0.12 | 0.04 |
| Other income (expense): | Weighted average shares used to compute net (loss) income per share – diluted | 309,191 | 311,484 | 308,732 | 312,381 |

### Income Statement (Three Months Ended June 30,)

| | Three Months Ended June 30, – 2026 – Net Loss | Three Months Ended June 30, – 2026 – Basic EPS | Three Months Ended June 30, – 2025 – Net Income | Three Months Ended June 30, – 2025 – Basic EPS | Six Months Ended June 30, – 2026 – Net Loss | Six Months Ended June 30, – 2026 – Basic EPS | Six Months Ended June 30, – 2025 – Net Income | Six Months Ended June 30, – 2025 – Basic EPS |
|---|---:|---:|---:|---:|---:|---:|---:|---:|
| GAAP reported net (loss) income | -19,032 | -0.06 | 668 | 0 | -35,651 | -0.12 | 13,826 | 0.05 |
| Non-GAAP adjustments: | Stock compensation | 10,226 | 0.03 | 7,520 | 0.03 | 16,681 | 0.05 | 12,905 | 0.04 |
| Non-GAAP adjustments: | Interest expense on liability for sale of future royalties | 510 | 0 | 3,473 | 0.01 | 3,073 | 0.01 | 7,050 | 0.02 |
| Non-GAAP adjustments: | Sold portion of royalty revenue (1) | -3,237 | -0.01 | -3,123 | -0.01 | -6,512 | -0.02 | -6,123 | -0.02 |
| Non-GAAP adjustments: | (Gain) loss on foreign currency transaction | -486 | 0 | 5,363 | 0.02 | -1,804 | -0.01 | 7,872 | 0.03 |
| Non-GAAP adjustments: | Amortization of intangible assets acquired | 4,367 | 0.01 |  |  | 8,734 | 0.03 |  |  |
| Non-GAAP adjustments: | Change in fair value of contingent consideration | 4,992 | 0.02 |  |  | 7,769 | 0.03 |  |  |
| Non-GAAP adjustments: | Loss on settlement of debt |  |  |  |  | 917 | 0 |  |  |
| Non-GAAP adjustments: | Non-GAAP adjusted net (loss) income | -2,660 | -0.01 | 13,901 | 0.05 | -6,793 | -0.03 | 35,530 | 0.12 |
| Non-GAAP adjustments: | Weighted average shares used to compute net (loss) income per share – basic | 309,191 |  | 304,954 |  | 308,732 |  | 304,222 |  |

### Balance Sheet (June 30, 2026 — MANNKIND CORPORATION AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS (In thousands except share and per share data))

| | June 30, 2026 | December 31, 2025 |
|---|---:|---:|
| Current assets: | Cash and cash equivalents | 52,929 | 74,882 |
| Current assets: | Short-term investments | 58,201 | 96,464 |
| Current assets: | Accounts receivable, net | 43,207 | 38,367 |
| Current assets: | Inventory | 44,419 | 35,313 |
| Current assets: | Prepaid expenses and other current assets | 46,956 | 46,553 |
| Current assets: | Total current assets | 245,712 | 291,579 |
| Current assets: | Restricted cash | 749 | 745 |
| Current assets: | Long-term investments |  | 5,012 |
| Current assets: | Property and equipment, net | 85,160 | 82,423 |
| Current assets: | Goodwill | 67,595 | 67,595 |
